Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma implant MINIject put to the test in everyday eye clinics

NCT ID NCT05269680

Disease control Sponsor: iSTAR Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry tracks 320 adults with open-angle glaucoma who receive the MINIject implant, a tiny device placed in the eye to help drain fluid and lower pressure. Researchers collect information on any unexpected complications and how surgeons rate the device's ease of use over two years. The goal is to see how well the implant performs in real-world medical practice, outside of controlled studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MINIject implant
What this could lead to
If the data confirm MINIject is safe and easy to use in routine care, it could support wider adoption of this implant for managing open-angle glaucoma.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove effectiveness. Unexpected complications or device issues may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patient diagnosed with open angle glaucoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18+ years * diagnosed with open angle glaucoma, who has been or will be implanted with CE-marked MINIject * able to give consent Exclusion Criteria: * eyes with angle closure glaucoma * eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle * patients with known intolerance or hypersensitivity to silicone * patients unable to give consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

Contacts and locations

Locations

  • Asklepios Klinik Nord - Heidberg Klinik für Augenheilkunde

    Hamburg, 22417, Germany

  • Augenzentrum ONE/Nordblick Augenklinik Bellevue

    Kiel, 24251, Germany

  • East Suffolk and North Essex NHS foundation trust

    Colchester, CO4 5JL, United Kingdom

  • Glaucoma Research Center, Swiss Visio, Montchoisi clinic

    Lausanne, 1006, Switzerland

  • Guy's and St Thomas' NHS Foundation Trust

    London, SE1 7EH, United Kingdom

  • Imperial College NHS Trust

    London, NW1 5QH, United Kingdom

  • International Innovative Ophtalmochirurgie GbR,

    Düsseldorf, 40212, Germany

  • Knappschaftskrankenhaus University Hospital

    Bochum, 44892, Germany

  • Maidstone and Tunbridge Wells NHS trust

    Maidstone, ME16 9QQ, United Kingdom

  • Medizinische Universität Graz

    Graz, 8010, Austria

  • Princess Alexandra Eye Pavilion, NHS Lothian

    Edinburgh, EH3 9HA, United Kingdom

  • Universitatsklinikum Schleswig-Holstein Klinik für Augneheilkunde

    Lübeck, 23538, Germany

  • Universitätsklinik für Augenheilkunde und Optometrie

    Vienna, 1090, Austria

  • Universitätsklinik für Augenheilkunde u. Optometrie

    Salzburg, A-5020, Austria

  • Universitätsklinikum Ulm / Augenklinik

    Ulm, 89070, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.